ArticleFrontiers in pharmacology2025
Opposing profiles of Netrin-1 and adiponectin in metabolic inflammation and insulin resistance.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomarkers and Endothelial Damage in Obesity: An Insight into the Pharmacological Modulation.International journal of molecular sciences · 2026Review
- Cholesterol, high-density lipoprotein, and glucose (CHG) index and incident impaired fasting glucose in Chinese adults: a retrospective longitudinal cohort study.Frontiers in nutrition · 2026Article
- The Immunometabolic Bridge: Targeting Metainflammation to Prevent the Transition from Obesity to Cardiovascular Disease.Journal of inflammation research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Obesity-driven low-grade inflammation contributes to insulin resistance (IR) and metabolic dysfunction. Beyond its axon-guidance role, Netrin-1 promotes macrophage retention in inflamed adipose tissue, whereas adiponectin exerts anti-inflammatory, insulin-sensitizing effects. We aimed to compare serum Netrin-1, interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP), and adiponectin across metabolic profiles and assess their associations with systemic inflammation. Methods: We conducted an analytical cross-sectional study in adults (n = 60): metabolically healthy controls (C, n = 20), preclinical obesity (PO; HOMA-IR < 2.5, n = 20), and clinical obesity with insulin resistance (CO; HOMA-IR>2.5, n = 20). Anthropometrics, fasting glucose/insulin, lipid profile, and serum biomarkers were obtained; group differences and correlations were analyzed (non-parametric tests where appropriate). Results: Between-group testing showed higher Netrin-1 in CO versus controls (Kruskal-Wallis p = 0.013; C < CO), with no significant difference versus PO. IL-6 was elevated in both PO and CO versus controls (Kruskal-Wallis p < 0.001). hs-CRP peaked in PO versus both C and CO (Kruskal-Wallis p < 0.001). Adiponectin was lower in CO and inversely correlated with hs-CRP (r = -0.22) and IL-6 (r = -0.53, p < 0.001). Discussion: Circulating Netrin-1 and adiponectin display opposing profiles aligned with pro- versus anti-inflammatory signaling in metabolic dysfunction. These findings support the Netrin-1/adiponectin axis as an immunometabolic marker set in early IR states. The cross-sectional design limits causal inference; longitudinal studies integrating tissue-level measurements are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.